Agilon Health, Inc.

NYSE:AGL

Medical - Care Facilities

Healthcare
$90.53 +2.16%

+$2.26 today

Market cap
$1.52B
Beta
3.04
P/E (TTM)
-4.8
EPS (TTM)
-$22.50
52W Low $7.48High $118.25

Volume 0.79M

Average 0.41M

AGL Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Agilon Health, Inc.NYSE: AGL

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $1.42B fell 7.3% year over year, behind the -2.8% change in trailing-twelve-month revenue. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at +35.4% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 10 analysts of $5.88B (-0.8%) for the fiscal year ending Dec 2026, a step up from the -2.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.42B-9.5% QoQ
Last fiscal yearDec 2025
$5.93B-2.1% YoY
LTMMar 2026
$5.82B-2.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.3%+4.0%+11.3 pp
1 year-2.1%-0.8%+1.3 pp
3-year CAGR+35.4%+5.5%-29.9 pp
5-year CAGR+8.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
5.93B USD
Year-over-year change
-2.1%
4-year CAGR
+40.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How AGL compares with its peers on the latest reported figures

  • AGL's LTM Mar 2026 revenue of $5.82B is the highest of the 10 companies compared; the peer median is $3.92M.
  • Its year-over-year change of -2.8% is the 5th highest of 7, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +35.4% compares with a peer median of +8.2%.
AGL Competitors Peer median
Revenue for AGL and competitors
Company Period LTM YoY 3-year CAGR
AGLAgilon Health, Inc.LTM Mar 2026$5.82B -2.8%+35.4%
DHDefinitive Healthcare Corp.LTM Mar 2026$238.26M -3.9%+2.7%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$81.18M +20.9%+17.6%
SLPSimulations Plus, Inc.LTM Feb 2026$80.54M +2.5%+13.7%
MCTACharming Medical Limited Class A Ordinary SharesFY2024$6.22M +3.4%—
NAKANakamoto Inc.LTM Mar 2026$3.92M +58.6%-21.7%
ANNXAnnexon, Inc.LTM Mar 2026$0 ——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ——
DBVTDBV Technologies S.A.LTM Mar 2026$0 -100.0%—
ENGNenGene Holdings Inc.LTM Apr 2026$0 ——
Peer median (excluding AGL) $3.92M+3.0%+8.2%

Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.52B2.39B4.32B6.06B5.93B
Cost of Revenue1.46B2.28B4.25B6.06B6.12B
Gross Profit65.74M111.36M69.67M4.84M(188.61M)
Gross Margin4.3%4.7%1.6%0.1%-3.2%
Research & Development00000
Selling, General & Admin427.5M207.79M285.76M268.91M238.54M
Operating Expenses437.99M216.74M301.8M296.97M232.46M
Depreciation & Amortization14.67M13.77M20.16M24.46M28.59M
EBITDA(362.16M)(72.41M)(167.64M)(218.19M)(368.86M)
EBITDA Margin-23.8%-3.0%-3.9%-3.6%-6.2%
Operating Income(372.24M)(105.38M)(232.13M)(292.13M)(421.08M)
Operating Margin-24.5%-4.4%-5.4%-4.8%-7.1%
Interest Income00000
Interest Expense6.15M4.48M6.66M6.18M6.64M
Other Income / Expenses(10.73M)14.71M37.67M43.3M16.98M
Income Before Tax(382.98M)(90.67M)(194.46M)(248.83M)(404.1M)
Pre-Tax Margin-25.2%-3.8%-4.5%-4.1%-6.8%
Income Tax Expense886K1.64M791K1.45M1.25M
Net Income(406.49M)(106.55M)(262.6M)(260.15M)(405.35M)
Net Margin-26.7%-4.5%-6.1%-4.3%-6.8%
EPS (Basic)(27.25)(6.50)(16.00)(15.75)(24.50)
EPS (Diluted)(27.25)(6.50)(16.00)(15.75)(24.50)
Weighted Avg Shares14.92M16.33M16.36M16.44M16.56M
Weighted Avg Shares (Diluted)14.92M16.33M16.36M16.44M16.56M

Agilon Health, Inc.

NYSE:AGL

Intrinsic Alpha fair value

Locked

Current Price

$90.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.